/CTABF

CTABF Stock - Canntab Therapeutics Limited

Q: What is the analyst price target for CTABF?

Analyst price target information is not currently available for CTABF.

Q: What is CTABF's market cap?

Market capitalization information is not currently available for CTABF.

Healthcare|Drug Manufacturers - Specialty & Generic|OTC

$0.00+0.00%

+$0.00 (+0.00%) • Nov 28

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for CTABF

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2018

FY2019

FY2020

FY2021

FY2022

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.42

52W High$0.01

52W Low$0.00

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2022	FY2021	FY2020	FY2019	FY2018
Revenue	$293,362	N/A	$133,334	$240,000	$26,667
Gross Profit	$-939,011	$-263,312	$133,334	$143,614	$26,667
Gross Margin	-320.1%	N/A	100.0%	59.8%	100.0%
Operating Income	$-4,164,020	$-3,519,482	$-2,615,705	$-2,501,770	$-2,423,424
Net Income	$-3,689,186	$-4,419,782	$-2,607,244	$-2,458,578	$-2,408,413
Net Margin	-1257.6%	N/A	-1955.4%	-1024.4%	-9031.4%
EPS	$-0.10	$-0.13	$-0.10	$-0.10	$-0.11

Company Overview

Canntab Therapeutics Limited, a phytopharmaceutical company, engages in the research and development of advanced pharmaceutical grade formulations of cannabinoids in Canada. It offers oral dosage formulations of pharmaceutical cannabis, including sustained release cannabinoid formulations and pellets, immediate release cannabidiol formulations, modified-release multi-layer cannabinoid formulations, flash-melt cannabinoid formulations, and bi-layer cannabinoid tablets for treating sleep disorders, post-traumatic stress disorder, social anxiety, addiction, arthritis, general pain, pain management and appetite loss associated with cancer treatments, and addiction treatment therapy of opioids and other painkillers. Canntab Therapeutics Limited is headquartered in Markham, Canada.

Visit Website

Frequently Asked Questions about CTABF

What is CTABF's current stock price?

Canntab Therapeutics Limited (CTABF) is currently trading at $0.00 per share. The stock has moved +0.00% today.

What is the analyst price target for CTABF?

No analyst price targets are currently available for this stock.

What sector is Canntab Therapeutics Limited in?

Canntab Therapeutics Limited operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the OTC exchange.

What is CTABF's market cap?

Canntab Therapeutics Limited has a market capitalization of $0.00 billion, making it a small-cap company.

Does CTABF pay dividends?

No, Canntab Therapeutics Limited does not currently pay a dividend to shareholders.